A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
According to the current clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting beta(2) agonist therapy is recommended in patients with moderate-to-severe disease and an increased risk of exacerbations. However, ICS...
| Autores: | , , , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2017 |
| País: | España |
| Recursos: | Instituto de Salud Carlos III (ISCIII) |
| Repositorio: | Repisalud |
| Idioma: | inglés |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/20464 |
| Acesso em linha: | http://hdl.handle.net/20.500.12105/20464 |
| Access Level: | acceso abierto |
| Palavra-chave: | Algorithm Chronic obstructive pulmonary disease Exacerbations Inhaled corticosteroids Lung function Enfermedad Pulmonar Obstructiva Crónica Broncodilatadores Humanos Neumonía Corticoesteroides Ensayos Clínicos Controlados Aleatorios como Asunto Administración por Inhalación Agonistas de Receptores Adren�rgicos beta 2 Privación de Tratamiento Adrenergic beta-2 Receptor Agonists Randomized Controlled Trials as Topic Administration, Inhalation Adrenal Cortex Hormones Pulmonary Disease, Chronic Obstructive Humans Withholding Treatment Bronchodilator Agents Pneumonia |
| Resumo: | According to the current clinical practice guidelines for chronic obstructive pulmonary disease (COPD), the addition of inhaled corticosteroids (ICS) to long-acting beta(2) agonist therapy is recommended in patients with moderate-to-severe disease and an increased risk of exacerbations. However, ICS are largely overprescribed in clinical practice, and most patients are unlikely to benefit from long-term ICS therapy. Evidence from recent randomized-controlled trials supports the hypothesis that ICS can be safely and effectively discontinued in patients with stable COPD and in whom ICS therapy may not be indicated, without detrimental effects on lung function, health status, or risk of exacerbations. This article summarizes the evidence supporting the discontinuation of ICS therapy, and proposes an algorithm for the implementation of ICS withdrawal in patients with COPD in clinical practice. Given the increased risk of potentially serious adverse effects and complications with ICS therapy (including pneumonia), the use of ICS should be limited to the minority of patients in whom the treatment effects outweigh the risks. |
|---|